title: [Medical treatment of renal cell carcinoma].
abstract: OBJECTIVE
  To describe drugs used in renal cell carcinoma.
  
  
  METHODS
  Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies websites (HAS and ANSM).
  
  
  RESULTS
  Since 2007, a total of three different therapeutic classes in the management of metastatic renal cell carcinoma are available. These three classes are tyrosine kinase inhibitors with sunitinib and sorafenib, the anti-VEGF antibodies (bevacizumab which is associated with alpha interferon in the treatment of advanced kidney cancer) and mTOR inhibitors with temsirolimus and everolimus. These targeted therapies are a major progress in the treatment of patients with metastatic kidney cancer. The side effects encountered with these molecules are numerous but serious side effects are less than 5% of all reported side effects.
  
  
  CONCLUSIONS
  A better understanding of molecular mechanisms has enabled the development of new therapies for the treatment of metastatic renal cell carcinoma. In the future, a personalized approach taking into account the biology of each tumor could be created to provide a more targeted treatment.
authors.affiliation: Faculté de médecine, université d'Auvergne, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand cedex 1, France; Service d'urologie, hôpital G.-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France. Electronic address: lguy@chu-clermontferrand.fr.
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: J-O
authors.initials: JO
authors.lastname: Bay
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: H
authors.initials: H
authors.lastname: Mahammedi
authors.forename: F
authors.initials: F
authors.lastname: Bruyere
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D000068338:Everolimus; D006801:Humans; D007167:Immunotherapy; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use; D007376:Interleukin-2 / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D012955:Societies, Medical; D000077157:Sorafenib; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007211:Indoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; D000068338:Everolimus; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor; C082598:aldesleukin; D000077210:Sunitinib; D020123:Sirolimus
keywords: Anti-VEGF antibodies; Anticorps anti-VEGF; Cancer du rein; Inhibiteur de mTOR; Inhibiteur des tyrosines kinases; MTOR inhibitor; Renal cell carcinoma; Targeted therapy; Thérapie ciblée; Tyrosine kinase inhibitor